GSK’s Hal Barron On R&D Progress At TwoYear Mark
GSK’s Hal Barron On R&D Progress At TwoYear Mark
$131.00
Hal Barron, Chief scientific officer at GSK recently spoke about winning the hearts and minds of 10,000 R&D employees and adopting practices from acquired company, Tesaro. In Vivo covers the talk topics including how doubters are coming around amid recent successful approvals
Publisher: InVivo
- Description
GlaxoSmithKline PLC is transforming its culture with a new emphasis on clear decision making and a focus on “smart risk taking”. Speaking at an Endpoints News UKBIO19 event in London, chief scientific officer and president of R&D, Hal Barron said this cultural transformation is already making an impact. In Vivo provides details about how a past, failed, consensus-driven approach to decision making drove his initial efforts to create a cultural change among the company’s 10,000 R&D employees so that each project would have a clear “single accountable decision-maker.” Two years later, Barron reports people noting that he didn’t just talk about a new strategy; it’s actually taking place.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Testing Ranitidine with Too Much Heat Could Generate NDMA, FDA Say 
Sign up to the